SCHEMBL18876366

SCHEMBL18876366

Fc1cc(-c2ccco2)cs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.42
TAAR1 Q96RJ0 2/20 0.42
MAPT P10636 4/20 0.42
HSD17B10 Q99714 4/20 0.42
ERN1 O75460 2/20 0.41
KEAP1 Q14145 1/20 0.39
MAPK14 Q16539 1/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 3/20 0.38
POLB P06746 2/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
ALOX15 P16050 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
PKM P14618 2/20 0.38
USP2 O75604 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28195936 0.77 TAAR1 (0.52) TOP1TAAR1MAPTHSD17B10KEAP1
SCHEMBL18876368 0.77 TOP1 (0.42) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL18876434 0.74 TAAR1 (0.41) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL7017974 0.74 TOP1 (0.41) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL6193416 0.74 ERN1 (0.49) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL27624181 0.73 KEAP1 (0.46) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL18879698 0.73 TOP1 (0.40) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL19662062 0.71 TAAR1 (0.58) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL18876483 0.71 ERN1 (0.49) TOP1TAAR1MAPTHSD17B10ERN1
SCHEMBL14019380 0.70 KMT2A (0.46) TOP1TAAR1MAPTHSD17B10ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11193065-B2 Liquid crystal composition, method of producing the same, and retardation film constituted from the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-07 US disclosed
US-20200165519-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-05-28 US disclosed
US-20190276744-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-09-12 US disclosed
US-10407619-B2 Liquid crystal composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-09-10 US disclosed
US-20170335191-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-11-23 US disclosed
US-20170335191-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-11-23 US disclosed
US-20170306234-A1 LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-26 US disclosed
US-20170306234-A1 LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-26 US disclosed
US-20170283700-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-05 US disclosed
US-20170145312-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170335191-A1 LIQUID CRYSTAL COMPOSITION RCC1, CCDC47, ACIN1 TOP1 905/4885TAAR1 3806/4885MAPT 57/4885
US-10407619-B2 Liquid crystal composition RCC1, CCDC47, ACIN1 TOP1 905/4885TAAR1 3806/4885MAPT 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.